Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
Zealand Pharma A/S in Denmark is seeking a Senior Laboratory Technician to run cell-based assays to screen candidate drugs and contribute to optimization and automation of laboratory workflows.
You will work with a team of scientists in Molecular Pharmacology, generate high-quality in vitro data, maintain lab equipment, and document work in ELN, supporting projects across drug discovery.
Does it excite you to work with cell-based assays to advance innovative peptide-based medicines, and do you have experience with assay automation and liquid handlers? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
As Senior Laboratory Technician, you will be running cell-based assays to screen and profile candidate drugs in collaboration with other technicians and scientists in the Molecular Pharmacology department. In addition, you will also contribute to the optimization and automation of our laboratory workflows.
This role offers a unique opportunity to make a significant contribution to the advancement of our projects by delivering high-quality in vitro data.
You have a mindset aligned with the Zealand values, with curiosity to acquire new skills and learn new methods. You bring a positive attitude and drive, and work both independently and collaboratively. You communicate clearly and have a good understanding of written and spoken English (company language). Further, you have:
You will be part of a department of 17 scientists and 9 technicians dedicated to advancing research and development through generation of in vitro pharmacology and biomarker data, and development of cell-based model systems to deepen understanding of drug mechanism of action. The department is organized into two teams to ensure close managerial support and scientific guidance, and works collaboratively across molecular biology, biochemical, biophysical, and cellular assay platforms to support identification, optimization, and characterization of drug candidates. The position is within our In vitro profiling and signaling team, which focuses on cell-based signaling and binding assays for compound profiling and mechanism-of-action studies.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a team in the U.S. For more information about Zealand Pharma's business and activities, please visit www.zealandpharma.com.
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes.
In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives.
Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome.
For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies.
For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.